Patient-Focused Drug Development for Vitiligo; Public Meeting; Request for Comments
| Published date | 12 February 2020 |
| Citation | 85 FR 8004 |
| Record Number | 2020-02767 |
| Section | Notices |
| Court | Food And Drug Administration,Health And Human Services Department |
Federal Register, Volume 85 Issue 29 (Wednesday, February 12, 2020)
[Federal Register Volume 85, Number 29 (Wednesday, February 12, 2020)]
[Notices]
[Pages 8004-8006]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-02767]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2020-N-0255]
Patient-Focused Drug Development for Vitiligo; Public Meeting;
Request for Comments
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public meeting; request for comments.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is
announcing the following public meeting entitled ``Patient-Focused Drug
Development for Vitiligo.'' The purpose of the public meeting is to
allow FDA to obtain patient perspectives on the impact of vitiligo on
daily life, patient views on treatment approaches, and decision factors
considered when selecting a treatment.
DATES: The public meeting will be held on March 30, 2020, from 1 p.m.
to 5 p.m. Submit either electronic or written comments on this public
meeting by June 1, 2020. See the SUPPLEMENTARY INFORMATION section for
registration date and information.
ADDRESSES: The public meeting will be held at FDA's White Oak Campus,
10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room
(Rm. 1503), Silver Spring, MD 20993. Entrance for the public meeting
participants (non-FDA employees) is through Building 1 where routine
security check procedures will be performed. For parking and security
information, please refer to https://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm.
You may submit comments as follows. Please note that late, untimely
filed comments will not be considered. Electronic comments must be
submitted on or before June 1, 2020. The https://www.regulations.gov
electronic filing system will accept comments until 11:59 p.m. Eastern
Time at the end of June 1, 2020. Comments received by mail/hand
delivery/courier (for written/paper submissions) will be considered
timely if they are postmarked or the delivery service acceptance
receipt is on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and
[[Page 8005]]
identified, as confidential, if submitted as detailed in
``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2020-N-0255 for ``Patient-Focused Drug Development on Vitiligo;
Public Meeting; Request for Comments.'' Received comments, those filed
in a timely manner (see ADDRESSES), will be placed in the docket and,
except for those submitted as ``Confidential Submissions,'' publicly
viewable at https://www.regulations.gov or at the Dockets Management
Staff between 9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Shannon Cole, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6306, Silver Spring, MD 20993-0002, 301-
796-9208, [email protected].
SUPPLEMENTARY INFORMATION:
I. Background
This meeting will provide FDA the opportunity to obtain patient and
patient representative input on the aspects of vitiligo that matter
most to patients, including how it affects daily life, and on current
approaches to treating vitiligo. Vitiligo is an autoimmune disease that
causes the loss of skin color. The loss of color can affect skin, hair,
and other areas of the body. The area affected by color loss can range
in individual patients from small discrete areas to near total
involvement. Although there is no cure or FDA-approved treatment for
repigmentation, there are available therapies, such as prescription
medications or non-drug therapies, which may often be used to manage
aspects of vitiligo. FDA is interested in patients' (including adult
and pediatric patients) perspectives on: (1) The impact of their
vitiligo; (2) treatment approaches; and (3) decision factors considered
when selecting a treatment.
The questions that will be asked of patients and patient
representatives at the meeting are listed in the following section and
organized by topic. For each topic, a brief initial patient panel
discussion will begin the dialogue. This discussion will be followed by
a facilitated discussion inviting comments from other patients and
patient representatives. In addition to input generated through this
public meeting, FDA is interested in receiving patient and patient
representative input addressing these questions through written
comments, which can be submitted to the public docket (see ADDRESSES).
When submitting comments, if you are commenting on behalf of a patient,
please indicate that you are doing so and answer the following
questions as much as possible from the patient's perspective.
FDA will post the agenda and other meeting materials approximately
5 days before the meeting at: https://www.fda.gov/drugs/news-events-human-drugs/public-meeting-patient-focused-drug-development-vitiligo-03302020-03302020.
II. Topics for Discussion at the Public Meeting
Topic 1: Health Effects and Daily Impacts That Matter Most to Patients
1. Which aspects of vitiligo have the most significant impact on
your life? (Examples may include depigmentation, itching, sensitivity
to sunlight, etc.)
2. Are there specific activities that are important to you but that
you cannot do at all or as fully as you would like because of your
vitiligo? (Examples of activities may include participating in social
events, playing sports, being outside in the sunlight, etc.)
How does your vitiligo and its impacts affect your daily life on
the best days? On the worst days?
3. How has your vitiligo changed over time?
a. How has your vitiligo changed from childhood to adulthood (such
as vitiligo severity, disease acceptance)?
b. Would you define your vitiligo today as being well-managed?
4. What worries you most about your vitiligo?
Is there a particular body area affected by vitiligo (such as face,
hands, limbs) that is of most concern to you?
Topic 2: Patients' Perspectives on Current Approaches to Treatment
1. What are you currently doing to help treat your vitiligo?
(Examples may include prescription medicines, over-the-counter
products, and other therapies, including non-drug therapies such as
diet modification.)
How has your treatment regimen changed over time, and why?
2. How well does your current treatment regimen treat the most
significant aspects of your vitiligo? For example, how well do your
treatments improve your ability to do specific activities?
3. What are the most significant downsides to your current
treatments, and how do they affect your daily life? (Examples of
downsides may include bothersome side effects, depigmentation of
affected area is more noticeable, hospital treatments, etc.)
4. Assuming there is no complete cure for your vitiligo, what
specific things would you look for in an ideal treatment for your
vitiligo?
Is there a particular body area affected by vitiligo (such as face,
hands, limbs) that you would prioritize for treatment?
5. What factors do you consider when making decisions about
selecting a course of treatment?
III. Participating in the Public Meeting
Registration: To register for the public meeting, visit https://vitiligo_pfdd.eventbrite.com">https://vitiligo_pfdd.eventbrite.com. Please register by March 23, 2020.
Persons without access to the internet can call 301-796-9208 to
register. If you are unable to attend the meeting in person, you can
register to view a live webcast of the meeting. You will be asked to
indicate in your registration if you plan to attend in person or via
the webcast. Please
[[Page 8006]]
provide complete contact information for each attendee, including name,
title, affiliation, address, email, and telephone.
Registration is free and based on space availability, with priority
given to early registrants. Persons interested in attending this public
meeting must register by March 23, 2020, 11:59 p.m. Eastern Time. Early
registration is recommended because seating is limited; therefore, FDA
may limit the number of participants from each organization. If time
and space permit, onsite registration on the day of the public meeting
will be provided beginning at 12 p.m.
If you need special accommodations due to a disability, please
contact Shannon Cole (see FOR FURTHER INFORMATION CONTACT) no later
than March 23, 2020.
Panelist Selection: Patients or patient representatives who are
interested in presenting comments as part of the initial panel
discussions will be asked to indicate in their registration which
topic(s) they wish to address. These patients or patient
representatives also will be asked to send [email protected] a
brief summary of responses to the topic questions by March 9, 2020.
Panelists will be notified of their selection approximately 7 days
before the public meeting. We will try to accommodate all patients and
patient stakeholders who wish to speak, either through the panel
discussion or audience participation; however, the duration of comments
may be limited by time constraints.
Open Public Comment: There will be time allotted during the meeting
for open public comment. Signup for this session will be on a first-
come, first-served basis on the day of the meeting. Individuals and
organizations with common interests are urged to consolidate or
coordinate and request time for a joint presentation. No commercial or
promotional material will be permitted to be presented or distributed
at the public meeting.
Persons attending FDA's meetings are advised that FDA is not
responsible for providing access to electrical outlets.
Streaming Webcast of the Public Meeting: This public meeting will
also be webcast. Please register for the webcast by visiting https://vitiligo_pfdd.eventbrite.com.
If you have never attended a Connect Pro event before, test your
connection at https://collaboration.fda.gov/common/help/en/support/meeting_test.htm. To get a quick overview of the Connect Pro program,
visit https://www.adobe.com/go/connectpro_overview. FDA has verified
the website addresses in this document, as of the date this document
publishes in the Federal Register, but websites are subject to change
over time.
Transcripts: Please be advised that as soon as a transcript of the
public meeting is available, it will be accessible at https://www.regulations.gov. It may be viewed at the Dockets Management Staff
(see ADDRESSES). A link to the transcript will also be available on the
internet at https://www.fda.gov/drugs/news-events-human-drugs/public-meeting-patient-focused-drug-development-vitiligo-03302020-03302020.
Dated: February 6, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-02767 Filed 2-11-20; 8:45 am]
BILLING CODE 4164-01-P
